{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:05:06Z","timestamp":1753895106147,"version":"3.41.2"},"reference-count":44,"publisher":"Federa\u00e7\u00e3o das Associa\u00e7\u00f5es de Ginecologia e Obstetr\u00edcia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"DOI":"10.61622\/rbgo\/2024rbgo61","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:31:18Z","timestamp":1722454278000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of insulin-like growth factor II mrna-binding protein 3 (IMP3) expression with prognostic and morphological factors in endometrial cancer"],"prefix":"10.61622","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6441-5737","authenticated-orcid":false,"given":"Silas Otero Reis","family":"Salum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-6654","authenticated-orcid":false,"given":"Eduardo Batista","family":"Candido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-3410","authenticated-orcid":false,"given":"Maria Aparecida Cust\u00f3dio","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-5199","authenticated-orcid":false,"given":"Elida Paula Benquique","family":"Ojopi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6890-8774","authenticated-orcid":false,"given":"\u00c2ngela Favorito Santarem","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8486-7861","authenticated-orcid":false,"given":"Agnaldo Lopes da","family":"Silva-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"47794","reference":[{"issue":"1","key":"key20240731134314_B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","unstructured":"1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: 10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"key20240731134314_B2","doi-asserted-by":"crossref","DOI":"10.32635\/2176-9745.RBC.2023v69n1.3700","article-title":"Estimativa de incid\u00eancia de c\u00e2ncer no Brasil, 2023-2025","volume":"69","author":"Santos","year":"2023","unstructured":"2. Santos MO, Lima FC, Martins LF, Oliveira JF, Almeida LM, Cancela MC. Estimativa de incid\u00eancia de c\u00e2ncer no Brasil, 2023-2025. Rev Bras Cancerol. 2023;69(1):e-213700.","journal-title":"Rev Bras Cancerol"},{"issue":"1","key":"key20240731134314_B3","article-title":"Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols","volume":"23","author":"Yang","year":"2023","unstructured":"3. Yang Z, Yang X, Liu X, Ma K, Meng YT, Yin HF, et al. Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols. BMC Cancer. 2023;23(1):243. doi: 10.1186\/s12885-023-10706-8","journal-title":"BMC Cancer"},{"issue":"1","key":"key20240731134314_B4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000152","article-title":"Endometrial cancer: molecular classification and future treatments","volume":"1","author":"Corr","year":"2022","unstructured":"4. Corr B, Cosgrove C, Spinosa D, Guntupalli S. Endometrial cancer: molecular classification and future treatments. BMJ Med. 2022;1(1):e000152. doi: 10.1136\/bmjmed-2022-000152","journal-title":"BMJ Med"},{"issue":"3","key":"key20240731134314_B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/ijgc-2022-003772","article-title":"Update in the molecular classification of endometrial carcinoma","volume":"33","author":"L\u00e9on-Castillo","year":"2023","unstructured":"5. L\u00e9on-Castillo A. Update in the molecular classification of endometrial carcinoma. Int J Gynecol Cancer. 2023;33(3):333-42. doi: 10.1136\/ijgc-2022-003772","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"key20240731134314_B6","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/ijc.31961","article-title":"Risk factors for endometrial cancer: an umbrella review of the literature","volume":"145","author":"Raglan","year":"2019","unstructured":"6. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019;145(7):1719-30. doi: 10.1002\/ijc.31961","journal-title":"Int J Cancer"},{"issue":"5","key":"key20240731134314_B7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jnci\/djad014","article-title":"Risk prediction models for endometrial cancer: development and validation in an international consortium","volume":"115","author":"Shi","year":"2023","unstructured":"7. Shi J, Kraft P, Rosner BA, Benavente Y, Black A, Brinton LA, et al. Risk prediction models for endometrial cancer: development and validation in an international consortium. J Natl Cancer Inst. 2023;115(5):552-9. doi: 10.1093\/jnci\/djad014","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"key20240731134314_B8","first-page":"733","article-title":"Epidemiology, classification and risk factors of endometrial cancer","volume":"72","author":"Varinot","year":"2022","unstructured":"8. Varinot J. [Epidemiology, classification and risk factors of endometrial cancer]. Rev Prat. 2022;72(7):733-7. French.","journal-title":"Rev Prat"},{"issue":"1","key":"key20240731134314_B9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","unstructured":"9. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7. doi: 10.1016\/0090-8258(83)90111-7","journal-title":"Gynecol Oncol"},{"key":"key20240731134314_B10","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2021.151861","article-title":"A prediction model based on clinical and histological features for predicting recurrence in patients with stage I-II endometrial cancer after surgical treatment","volume":"56","author":"Song","year":"2022","unstructured":"10. Song W, Zhao Y. A prediction model based on clinical and histological features for predicting recurrence in patients with stage I-II endometrial cancer after surgical treatment. Ann Diagn Pathol. 2022;56:151861. doi: 10.1016\/j.anndiagpath.2021.151861","journal-title":"Ann Diagn Pathol"},{"issue":"3","key":"key20240731134314_B11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0115426506021003255","article-title":"The use of selected nutrition supplements and complementary and alternative medicine in liver disease","volume":"21","author":"Hanje","year":"2006","unstructured":"11. Hanje AJ, Fortune B, Song M, Hill D, McClain C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract. 2006;21(3):255-72. doi: 10.1177\/0115426506021003255","journal-title":"Nutr Clin Pract"},{"issue":"2","key":"key20240731134314_B12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-15-0104","article-title":"Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer","volume":"22","author":"Yang","year":"2016","unstructured":"12. Yang JY, Werner HM, Li J, Westin SN, Lu Y, Halle MK, et al. Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clin Cancer Res. 2016;22(2):513-23. doi: 10.1158\/1078-0432.CCR-15-0104","journal-title":"Clin Cancer Res"},{"issue":"7488","key":"key20240731134314_B13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12881","article-title":"Landscape of genomic alterations in cervical carcinomas","volume":"506","author":"Ojesina","year":"2014","unstructured":"13. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 2014;506(7488):371-5. doi: 10.1038\/nature12881","journal-title":"Nature"},{"issue":"9","key":"key20240731134314_B14","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-014-0403-3","article-title":"Current status of molecular biomarkers in endometrial cancer","volume":"16","author":"Werner","year":"2014","unstructured":"14. Werner HM, Salvesen HB. Current status of molecular biomarkers in endometrial cancer. Curr Oncol Rep. 2014;16(9):403. doi: 10.1007\/s11912-014-0403-3","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"key20240731134314_B15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/PAS.0000000000001209","article-title":"Targeted molecular and immunohistochemical analyses of endometrial clear cell carcinoma show that POLE mutations and DNA mismatch repair protein deficiencies are uncommon","volume":"43","author":"Baniak","year":"2019","unstructured":"15. Baniak N, Fadare O, K\u00f6bel M, DeCoteau J, Parkash V, Hecht JL, et al. Targeted molecular and immunohistochemical analyses of endometrial clear cell carcinoma show that POLE mutations and DNA mismatch repair protein deficiencies are uncommon. Am J Surg Pathol. 2019;43(4):531-7. doi: 10.1097\/PAS.0000000000001209","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"key20240731134314_B16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5603\/GP.a2017.0062","article-title":"Biological markers with potential clinical value in endometrial cancer - review of the literature","volume":"88","author":"Taoussi","year":"2017","unstructured":"16. Taoussi N, Alghamdi A, Futyma K, Rechberger T. Biological markers with potential clinical value in endometrial cancer - review of the literature. Ginekol Pol. 2017;88(6):331-6. doi: 10.5603\/GP.a2017.0062","journal-title":"Ginekol Pol"},{"issue":"1","key":"key20240731134314_B17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5644\/ama2006-124.245","article-title":"Genomic-based therapy of gynecologic malignancies","volume":"48","author":"Markman","year":"2019","unstructured":"17. Markman M. Genomic-based therapy of gynecologic malignancies. Acta Med Acad. 2019;48(1):84-9. doi: 10.5644\/ama2006-124.245","journal-title":"Acta Med Acad"},{"issue":"3","key":"key20240731134314_B18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PAP.0000000000000021","article-title":"Oncofetal protein IMP3, a new cancer biomarker","volume":"21","author":"Gong","year":"2014","unstructured":"18. Gong Y, Woda BA, Jiang Z. Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol. 2014;21(3):191-200. doi: 10.1097\/PAP.0000000000000021","journal-title":"Adv Anat Pathol"},{"issue":"22","key":"key20240731134314_B19","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/sj.onc.1201110","article-title":"Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein","volume":"14","author":"M\u00fceller-Pillasch","year":"1997","unstructured":"19. M\u00fceller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14(22):2729-33. doi: 10.1038\/sj.onc.1201110","journal-title":"Oncogene"},{"key":"key20240731134314_B20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2014.07.006","article-title":"The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer","volume":"29","author":"Lederer","year":"2014","unstructured":"20. Lederer M, Bley N, Schleifer C, H\u00fcttelmaier S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 2014;29:3-12. doi: 10.1016\/j.semcancer.2014.07.006","journal-title":"Semin Cancer Biol"},{"key":"key20240731134314_B21","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.632219","article-title":"IGF2BP1, a conserved regulator of RNA turnover in cancer","volume":"8","author":"Gla\u00df","year":"2021","unstructured":"21. Gla\u00df M, Misiak D, Bley N, M\u00fcller S, Hagemann S, Busch B, et al. IGF2BP1, a conserved regulator of RNA turnover in cancer. Front Mol Biosci. 2021;8:632219. doi: 10.3389\/fmolb.2021.632219","journal-title":"Front Mol Biosci"},{"issue":"12","key":"key20240731134314_B22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/modpathol.3800960","article-title":"Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations","volume":"20","author":"Li","year":"2007","unstructured":"22. Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007;20(12):1263-8. doi: 10.1038\/modpathol.3800960","journal-title":"Mod Pathol"},{"issue":"2","key":"key20240731134314_B23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PAS.0b013e3181483ff8","article-title":"The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma","volume":"32","author":"Zheng","year":"2008","unstructured":"23. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32(2):304-15. doi: 10.1097\/PAS.0b013e3181483ff8","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"key20240731134314_B24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/his.12096","article-title":"ER+ \/PR+ \/TFF3+ \/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases","volume":"62","author":"Mhawech-Fauceglia","year":"2013","unstructured":"24. Mhawech-Fauceglia P, Yan L, Liu S, Pejovic T. ER+ \/PR+ \/TFF3+ \/IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology. 2013;62(7):976-85. doi: 10.1111\/his.12096","journal-title":"Histopathology"},{"issue":"12","key":"key20240731134314_B25","first-page":"1607","article-title":"Claudins as diagnostic and prognostic markers in gynecological cancer","volume":"24","author":"Szab\u00f3","year":"2009","unstructured":"25. Szab\u00f3 I, Kiss A, Schaff Z, Sobel G. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol. 2009;24(12):1607-15. doi: 10.14670\/HH-24.1607","journal-title":"Histol Histopathol"},{"key":"key20240731134314_B26","first-page":"116","volume-title":"Verh Dtsch Ges Pathol","author":"B\u00f6cker","year":"2002","unstructured":"26. B\u00f6cker W. [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. Verh Dtsch Ges Pathol. 2002;86:116-9. German."},{"issue":"2","key":"key20240731134314_B27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","unstructured":"27. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103-4. doi: 10.1016\/j.ijgo.2009.02.012","journal-title":"Int J Gynaecol Obstet"},{"issue":"7447","key":"key20240731134314_B28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"28. Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. doi: 10.1038\/nature12113","journal-title":"Nature"},{"issue":"2","key":"key20240731134314_B29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2013.02.023","article-title":"Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial","volume":"129","author":"Brinton","year":"2013","unstructured":"29. Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129(2):277-84. doi: 10.1016\/j.ygyno.2013.02.023","journal-title":"Gynecol Oncol"},{"issue":"1","key":"key20240731134314_B30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00428-010-0939-z","article-title":"Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study","volume":"457","author":"Zannoni","year":"2010","unstructured":"30. Zannoni GF, Vellone VG, Arena V, Prisco MG, Scambia G, Carbone A, et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch. 2010;457(1):27-34. doi: 10.1007\/s00428-010-0939-z","journal-title":"Virchows Arch"},{"issue":"5","key":"key20240731134314_B31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","unstructured":"31. Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180-8. doi: 10.1093\/annonc\/mdy058","journal-title":"Ann Oncol"},{"issue":"8","key":"key20240731134314_B32","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/S1470-2045(12)70213-9","article-title":"Markers for individualised therapy in endometrial carcinoma","volume":"13","author":"Salvesen","year":"2012","unstructured":"32. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 2012;13(8):e353-61. doi: 10.1016\/S1470-2045(12)70213-9","journal-title":"Lancet Oncol"},{"issue":"4","key":"key20240731134314_B33","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.22459","article-title":"RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma","volume":"48","author":"Jeng","year":"2008","unstructured":"33. Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008;48(4):1118-27. doi: 10.1002\/hep.22459","journal-title":"Hepatology"},{"key":"key20240731134314_B34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.humpath.2019.04.014","article-title":"Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study","volume":"89","author":"Visser","year":"2019","unstructured":"34. Visser NC, van der Putten LJ, van Egerschot A, Van de Vijver KK, Santacana M, Bronsert P, et al. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Hum Pathol. 2019;89:90-8. doi: 10.1016\/j.humpath.2019.04.014","journal-title":"Hum Pathol"},{"issue":"8","key":"key20240731134314_B35","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.humpath.2012.12.003","article-title":"Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance","volume":"44","author":"Fadare","year":"2013","unstructured":"35. Fadare O, Liang SX, Crispens MA, Jones HW, Khabele D, Gwin K, et al. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol. 2013;44(8):1508-15. doi: 10.1016\/j.humpath.2012.12.003","journal-title":"Hum Pathol"},{"issue":"1","key":"key20240731134314_B36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijsu.2012.11.021","article-title":"Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma","volume":"11","author":"Chen","year":"2013","unstructured":"36. Chen YL, Jeng YM, Hsu HC, Lai HS, Lee PH, Lai PL, et al. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma. Int J Surg. 2013;11(1):85-91. doi: 10.1016\/j.ijsu.2012.11.021","journal-title":"Int J Surg"},{"issue":"8","key":"key20240731134314_B37","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/jso.22108","article-title":"Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma","volume":"105","author":"Okada","year":"2012","unstructured":"37. Okada K, Fujiwara Y, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, et al. Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol. 2012;105(8):780-5. doi: 10.1002\/jso.22108","journal-title":"J Surg Oncol"},{"issue":"1","key":"key20240731134314_B38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/10520295.2011.591831","article-title":"Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer","volume":"87","author":"Findeis-Hosey","year":"2012","unstructured":"38. Findeis-Hosey JJ, Xu H. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer. Biotech Histochem. 2012;87(1):24-9. doi: 10.3109\/10520295.2011.591831","journal-title":"Biotech Histochem"},{"issue":"5","key":"key20240731134314_B39","first-page":"411","article-title":"Insights into endometrial serous carcinogenesis and progression","volume":"2","author":"Fadare","year":"2009","unstructured":"39. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2(5):411-32.","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"key20240731134314_B40","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/j.humpath.2014.06.031","article-title":"A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry","volume":"45","author":"Santacana","year":"2014","unstructured":"40. Santacana M, Maiques O, Valls J, Gatius S, Ab\u00f3 AI, L\u00f3pez-Garc\u00eda MA, et al. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Hum Pathol. 2014;45(12):2394-403. doi: 10.1016\/j.humpath.2014.06.031","journal-title":"Hum Pathol"},{"issue":"5","key":"key20240731134314_B41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/PAS.0b013e318247b7bb","article-title":"Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?","volume":"36","author":"Alvarez","year":"2012","unstructured":"41. Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol. 2012;36(5):753-61. doi: 10.1097\/PAS.0b013e318247b7bb","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"key20240731134314_B42","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/PAS.0000000000001737","article-title":"Corded and hyalinized and spindled endometrioid endometrial carcinoma: a clinicopathologic and molecular analysis of 9 tumors based on the TCGA classifier","volume":"45","author":"Safdar","year":"2021","unstructured":"42. Safdar NS, Thompson EF, Gilks CB, Isacson C, Bennett JA, Clarke B, et al. Corded and hyalinized and spindled endometrioid endometrial carcinoma: a clinicopathologic and molecular analysis of 9 tumors based on the TCGA classifier. Am J Surg Pathol. 2021;45(8):1038-46. doi: 10.1097\/PAS.0000000000001737","journal-title":"Am J Surg Pathol"},{"key":"key20240731134314_B43","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ejogrb.2020.10.031","article-title":"Molecular characterization in the prediction of disease extent in endometrial carcinoma","volume":"256","author":"Kolehmainen","year":"2021","unstructured":"43. Kolehmainen AM, Pasanen AM, Koivisto-Korander RL, B\u00fctzow RC, Loukovaara MJ. Molecular characterization in the prediction of disease extent in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2021;256:478-83. doi: 10.1016\/j.ejogrb.2020.10.031","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20240731134314_B44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.humpath.2017.11.006","article-title":"Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study","volume":"72","author":"Espinosa","year":"2018","unstructured":"44. Espinosa I, De Leo A, D'Angelo E, Rosa-Rosa JM, Corominas M, Gonzalez A, et al. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Hum Pathol. 2018;72:100-6. doi: 10.1016\/j.humpath.2017.11.006","journal-title":"Hum Pathol"}],"container-title":["Revista Brasileira de Ginecologia e Obstetr\u00edcia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journalrbgo.org\/wp-content\/uploads\/sites\/4\/articles_xml\/1806-9339-rbgo-46-e-rbgo61\/1806-9339-rbgo-46-e-rbgo61.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T16:52:53Z","timestamp":1724345573000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalrbgo.org\/article\/association-of-insulin-like-growth-factor-ii-mrna-binding-protein-3-imp3-expression-with-prognostic-and-morphological-factors-in-endometrial-cancer\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":44,"alternative-id":["10.61622\/rbgo\/2024rbgo61"],"URL":"https:\/\/doi.org\/10.61622\/rbgo\/2024rbgo61","relation":{},"ISSN":["0100-7203","1806-9339"],"issn-type":[{"type":"print","value":"0100-7203"},{"type":"electronic","value":"1806-9339"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e-rbgo61"}}